These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 27040278)
1. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278 [TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905 [TBL] [Abstract][Full Text] [Related]
3. Reemergence of Splenectomy for ITP Second-line Treatment? Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009 [TBL] [Abstract][Full Text] [Related]
4. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience. Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069 [TBL] [Abstract][Full Text] [Related]
5. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483 [TBL] [Abstract][Full Text] [Related]
8. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087 [TBL] [Abstract][Full Text] [Related]
9. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360 [TBL] [Abstract][Full Text] [Related]
12. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura. Johansson E; Engervall P; Landgren O; Grimfors G; Widell S; Rezai S; Björkholm M Eur J Haematol; 2006 Jul; 77(1):61-6. PubMed ID: 16573739 [TBL] [Abstract][Full Text] [Related]
13. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR; Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390 [TBL] [Abstract][Full Text] [Related]
14. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Shanafelt TD; Madueme HL; Wolf RC; Tefferi A Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692 [TBL] [Abstract][Full Text] [Related]
15. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694 [TBL] [Abstract][Full Text] [Related]
17. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354 [TBL] [Abstract][Full Text] [Related]
18. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Derumeaux H; Adoue D Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066 [TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. Park YH; Yi HG; Lee MH; Kim CS; Lim JH Int J Hematol; 2016 Feb; 103(2):180-8. PubMed ID: 26588926 [TBL] [Abstract][Full Text] [Related]
20. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Aleem A; Alaskar AS; Algahtani F; Rather M; Almahayni MH; Al-Momen A Int J Hematol; 2010 Sep; 92(2):283-8. PubMed ID: 20640541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]